CXCR4 and cancer: Targeting CXCR4 with radiopharmaceuticals has emerged as a viable method of identifying and potentially treating patients with CXCR4-expressing cancers, with [68Ga]Ga-Pentixafor and [177Lu]Lu-/[90Y]Y-Pentixather leading the way in clinical studies [22,23].